儿科产品是亚宝药业的重点品类，业绩会中，任蓬勃向财联社记者介绍，今年1-9月，公司儿科类产品实现营业收入6.76亿，同比增长1.23%，占总营收的31.85%。细分来看，“今年前三季度，意芽健脾凝胶实现销售收入同比增长24%；儿童清咽解热口服液实现销售收入同比增长64%；丁桂儿脐贴实现营收3.56亿元，同比下降8%。”公司总经理任伟表示。① Yabao Pharmaceutical said at the performance meeting that in the first three quarters of this year, the company's pediatric product revenue increased year-on-year. ② The company's director said that while revenue from betahistine hydrochloride injections declined, sales increased, and predicted that “the revenue decline will narrow during the year” in this category. ③ Yabao Pharmaceutical also explained the progress of the company's research pipeline, share repurchases, etc.
Finance Association, November 12 (Reporter He Fan) At the 2024 third quarter results briefing held today, Yabao Pharmaceutical (600351.SH) director Ren Fengbo said that in the first three quarters of this year, the company's pediatric product revenue increased year-on-year, while betastine hydrochloride injection revenue declined, but sales increased. It is expected that “the revenue decline will narrow during the year” in this category.
In addition, Yabao Pharmaceutical also explained the company's progress in the research pipeline, share repurchases, etc.
Pediatric products are a key category of Yabao Pharmaceutical. During the performance conference, Ren Fengbo explained to the Financial Federation reporter that in January-September of this year, the company's pediatric products achieved operating revenue of 0.676 billion yuan, an increase of 1.23% over the previous year, accounting for 31.85% of total revenue. Looking at the breakdown, “In the first three quarters of this year, Yiyajian Spleen Gel achieved a 24% year-on-year increase in sales revenue; children's antipyretic oral solution achieved a 64% year-on-year increase in sales revenue; and Ding Guier's umbilical patch achieved revenue of 0.356 billion yuan, a year-on-year decrease of 8%.” Ren Wei, general manager of the company, said.
Previously, sales declined due to the impact of the prescription drug betahistine hydrochloride injection due to collection. In the first half of the year, Yabao Pharmaceutical's revenue declined year-on-year. Regarding the drug's sales volume, Ren Pengbo told the Financial Federation reporter during this performance conference, “By the end of June 2024, the product's sales revenue had decreased 48% year on year. By the end of September 2024, the product had achieved sales revenue of 0.139 billion, down 47% year on year, and sales increased 20% year on year. It is expected that the revenue decline will narrow during the year.”
Yabao Pharmaceutical's new drug research and development progress has also attracted investors' attention. Ren Wei revealed that SY-005 has now completed IIa clinical trials, discovered indications for treating stroke during the research and development process, and obtained US patent authorization; the SY-009 project is in phase II clinical trials; and Chaigui granules to treat depression are in phase II clinical phase. Other products involving acute upper respiratory tract infections in children, pediatric cough variant asthma, pediatric eczema, pediatric pulmonary fever, cough and asthma are all in the pre-clinical stage.
Regarding the repurchase matter previously announced, Ren Pengbo told the Financial Federation reporter that as of October 31, 2024, the company had repurchased 0.7717 million shares through centralized bidding transactions. Currently, the repurchase is in progress normally, and the latest developments will be announced in early December. On September 3, Yabao Pharmaceutical announced that it plans to use 0.1 billion yuan to 0.15 billion yuan to repurchase shares for cancellation. The repurchase period shall not exceed 6 months from the date of review and approval by the shareholders' meeting, and the repurchase price shall not exceed 6.95 yuan/share.
